Psilocybin for major depressive disorder: An updated systematic review and meta-analysis of randomized clinical trials
Journal of Psychopharmacology October 31, 2024 Sepehr Aghajanian, Arman Shafiee, Samira Parvizi Omran et al. 12 citations
Psilocybin, a classic hallucinogen, produces a large and clinically observable reduction in depressive symptoms when added to supportive therapy, compared to baseline measurements and to placebo. The effect remains significant across various time intervals after administration. This systematic review and meta-analysis substantiates that psilocybin is superior to psychotherapy alone for treating depression, warranting further studies with larger samples and longer follow-up.